Protagonist Therapeutics (PTGX) Free Cash Flow by Year
Protagonist Therapeutics, Inc generated $56.1M in free cash flow in fiscal year 2025. This represents a decrease of 69.3% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $130.6M in free cash flow. The table below carries 12 fiscal years, from 2014 to 2025, and the quarters Protagonist Therapeutics, Inc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
PTGX Free Cash Flow by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
PTGX Free Cash Flow by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What free cash flow means
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.
More Protagonist Therapeutics, Inc financials
Frequently Asked Questions
What was Protagonist Therapeutics, Inc's free cash flow in fiscal year 2025?
Protagonist Therapeutics, Inc generated $56.1M in free cash flow in fiscal year 2025.
How fast is Protagonist Therapeutics, Inc's free cash flow growing?
Protagonist Therapeutics, Inc (PTGX) free cash flow fell by 69.3% year over year, from $182.8M to $56.1M in fiscal year 2025.
What is Protagonist Therapeutics, Inc's free cash flow over the last twelve months?
Protagonist Therapeutics, Inc (PTGX) reported $130.6M in free cash flow over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Protagonist Therapeutics, Inc's free cash flow changed over the years?
Across the 12 fiscal years this page covers, Protagonist Therapeutics, Inc (PTGX) free cash flow went from -$8.0M in fiscal year 2014 to $56.1M in fiscal year 2025.
What was Protagonist Therapeutics, Inc's free cash flow in the most recent quarter?
Protagonist Therapeutics, Inc (PTGX) reported $218.9M in free cash flow in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
What does free cash flow mean on a financial statement?
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Protagonist Therapeutics, Inc (PTGX) reported on that line in every period on record.